In a recent review published in Signal Transduction and Targeted Therapy, researchers presented recombinant adeno-associated virus (rAAV)-based genetic applications to treat human diseases. Study: ...

Refeyn, developer of pioneering mass photometry technology, expands its global adoption across contract research ...

Oxford, UK – 11 March 2022: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or the “Company"), a leading gene and cell therapy group, is pleased to announce that it has completed its deal with ...

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its off-the-shelf Rep/Cap plasmid offering, designed to streamline ...

A novel bioengineering strategy utilizing peptide display technology on the AAV1 capsid has successfully generated ...

It was the summer of 2020. Pandemic aside, things were going well for Tuyen Ong, M.D. The physician and biotech entrepreneur was heading up the opthamology franchise unit of Biogen following its ...

A mathematical model could help reduce the experimental effort needed to develop production processes for gene therapies. The digital twin, developed by a team at University College London (UCL) in ...

Supporting scale-up for early-phase AAV- and LVV-based gene and gene-modified cell therapy researchers and developers WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc ...

Osaka, Japan - A research team at The University of Osaka has unveiled the molecular mechanism behind genome ejection from adeno-associated virus (AAV) vectors, a crucial delivery vehicle in gene ...

Rentschler Biopharma launched an expanded service offering at its dedicated Advanced Therapy Medicinal Products (ATMP) site in Stevenage, U.K. The company introduced a new lentiviral vector ...